ESTRO 2024 - Abstract Book

S1697

Clinical - Lung

ESTRO 2024

Conclusion:

MR- SABR for central lung tumors resulted in grade ≥3 clinical toxicity in only 7% of patients, mostly due to bronchial stenosis or atelectasis. The 2-year local progression-free survival of 88%, after a median follow-up of 41 months, is encouraging. Additional data from ongoing prospective trials of MR-SABR are awaited to confirm our findings.

Keywords: Central, SABR, MR-guided

1801

Digital Poster

Effect of lung dose and prophylactic clarithromycin on the development of radiation pneumonitis

Takayuki Ohguri, HIirohide Itamura, Takahiro Morisaki, Subaru Tani

University of Occupational and Environmental Health, Therapeutic Radiology, Kitakyuhsu, Japan